EVOLUS, INC. Cash and Restricted Cash
EVOLUS, INC. (EOLS) had Cash and Restricted Cash of $45.17 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45.17M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $49.79M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $53.83M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $43.52M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $45.17M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $49.79M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $53.83M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $43.52M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $61.74M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $67.89M 10-Q · filed 2026-05-04 |
| 2024-12-31 | $86.95M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $85.03M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $93.67M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $96.96M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $62.84M 10-K · filed 2026-03-03 |
| 2023-09-30 | $38.69M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $41.70M 10-Q · filed 2024-07-31 |
| 2023-03-31 | $31.46M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $53.92M 10-K · filed 2026-03-03 |
| 2022-09-30 | $65.57M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $84.48M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $106.67M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $146.26M 10-K · filed 2025-03-04 |
| 2021-09-30 | $107.80M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $131.74M 10-Q · filed 2022-08-02 |
| 2021-03-31 | $22.17M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $102.56M 10-K · filed 2023-03-08 |
| 2020-09-30 | $85.13M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $29.77M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $34.65M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $109.89M 10-K · filed 2022-03-03 |
| 2019-09-30 | $39.12M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $30.29M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $54.37M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $93.16M 10-K · filed 2021-03-25 |
| 2018-09-30 | $105.17M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $43.59M 10-Q · filed 2019-08-12 |
| 2018-03-31 | $49.57M 10-Q · filed 2019-05-01 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-05 |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-02 |
| 2016-12-31 | $187.00K 10-K · filed 2019-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |